Clinical Trials Directory

Trials / Conditions / Systemic Scleroderma

Systemic Scleroderma

32 registered clinical trials studyying Systemic Scleroderma8 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingEfficacy and Safety of Firsekibart in the Treatment of Systemic Sclerosis
NCT07502105
Tongji HospitalN/A
Not Yet RecruitingEfficacy and Safety of Allogenic Cultured Adipose-derived Mesenchymal Stromal Cell Injections on MoUth Fibrosi
NCT07326033
University Hospital, ToulousePhase 2
Not Yet RecruitingCharacterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies
NCT07251179
University Hospital, Strasbourg, France
RecruitingDiffuse Cutaneous Scleroderma (DSSc) SFDI Study
NCT07090226
Boston UniversityN/A
RecruitingFamilial Systemic Scleroderma
NCT07343115
University Hospital, Strasbourg, France
RecruitingSafety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
NCT06056921
Chongqing Precision Biotech Co., LtdPhase 1
Active Not RecruitingLongitudinal Spatial Frequency Domain Imaging Study
NCT05672992
Boston UniversityN/A
Active Not RecruitingClinical Study of Divozilimab in Patients With Systemic Scleroderma
NCT05726630
BiocadPhase 3
RecruitingTBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Scleros
NCT04380831
City of Hope Medical CenterEARLY_Phase 1
RecruitingTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorde
NCT03816345
National Cancer Institute (NCI)Phase 1
CompletedRole of Eosinophil in Fibrogenesis of Systemic Sclerosis
NCT03816189
University Hospital, Lille
CompletedMicroparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis
NCT03575156
University Hospital, BordeauxN/A
UnknownBIOLOGICAL EXPLORATION OF THE VASCULAR FRACTION FROM THE ADIPOSE TISSUE OF PATIENTS WITH SCLERODERMIA
NCT03629002
Assistance Publique Hopitaux De Marseille
UnknownEvaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis
NCT03508375
Assistance Publique Hopitaux De MarseilleN/A
CompletedClinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 201
NCT03262922
Rennes University Hospital
CompletedTrial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
NCT02349009
Prism Pharma Co., Ltd.Phase 1 / Phase 2
CompletedTreatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells
NCT02213705
Assistance Publique - Hôpitaux de ParisPhase 1 / Phase 2
TerminatedStudy of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effec
NCT01559129
CelgenePhase 2
CompletedScleroderma Treatment With Autologous Transplant (STAT) Study
NCT01413100
Fred Hutchinson Cancer CenterPhase 2
TerminatedImmunoadsorption in Patients With Severe Systemic Sclerosis
NCT01410903
GWT-TUD GmbHN/A
CompletedImatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
NCT01309997
Lee, StephaniePhase 2
CompletedSildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY
NCT01295736
University Hospital, LillePhase 3
TerminatedEffectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic
NCT00628797
Nicolas HunzelmannPhase 1 / Phase 2
CompletedCLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study
NCT00522002
George Washington University
CompletedCardiac Repercussion of Systemic Sclerodermias
NCT00697736
Hospices Civils de LyonN/A
TerminatedPlacebo Controlled Trial of Bosentan in Scleroderma Patients
NCT00377455
Georgetown UniversityPhase 2
CompletedAllogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis
NCT00622895
Fred Hutchinson Cancer CenterPhase 1 / Phase 2
CompletedEffect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis
NCT00318175
Heinrich-Heine University, DuesseldorfPhase 2
CompletedCyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
NCT00278525
Northwestern UniversityPhase 2
CompletedEffects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis
NCT00318188
Assistance Publique - Hôpitaux de ParisN/A
CompletedScleroderma Lung Disease
NCT00004563
The University of Texas Health Science Center, HoustonPhase 3
WithdrawnLow-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Scleros
NCT01047072
Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumPhase 2